Pharmaceuticals
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...
2026-09-08 20:17
2067
/C O R R E C T I O N -- GCCL/
In the news release, "GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026," issued on September 8, 2026 by GCCL over PR Newswire, we are advised by the company that the name "Yoo-Hwa Choi" should read "Yuhwa Choi" throughout the release, as originally issued inadvertently. Co...
2026-09-08 16:05
2432
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 7, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published online clini...
2026-09-08 08:00
1815
Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio
– 5,600 participants from 19 countries discuss global bio innovation and the path forward – – Strengthened global regulatory cooperation, with a total of 23 meetings held with overseas regulators and industry, including 5 regulatory cooperation meetings – SEOUL, South Korea, Sept. 7, 2026 /PRNe...
2026-09-07 20:00
3111
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). * First Universal Consensus Across Six Independently-De...
2026-09-07 17:42
2574
CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply Capabilities
YANTAI, China, Sept. 7, 2026 /PRNewswire/ -- CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achievedEXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), becoming the first Chinese cell culture media supplier to r...
2026-09-07 14:00
1871
Rznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research
SEONGNAM, South Korea, Sept. 6, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in the high-efficiency production of circular RNA (circRNA) – a rapidly emerging modality ...
2026-09-07 12:36
1901
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today ann...
2026-09-07 08:46
2284
Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults
-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust neutralizing a...
2026-09-07 07:07
2424
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The share...
2026-09-07 07:00
5542
DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES
* Dimerix successfully enters into non-dilutive facility agreements to access A$34 million[1] with a syndicate of Australian and U.S. independent lenders, including the previously announced initial facility of A$10 million[2] * Facility terms for all Lenders substantially consistent with the p...
2026-09-04 19:00
4139
Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ -- Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies a...
2026-09-04 19:00
2699
Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)
Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of thePulmonary Artery Dener...
2026-09-03 19:53
2448
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden ...
2026-09-03 08:30
2884
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
HONG KONG, Sept. 2, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee (IDMC), met the key secondary endpo...
2026-09-03 05:00
2493
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
* Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 * Alteogen's fourth licensing agreement signed this year further accelerating the expansion of the Hybrozyme™ platform DAEJEON, South Korea, Sept. 2, 2026 /PRNewswire/ -- Al...
2026-09-02 19:00
3210
Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC
WUXI, China, Sept. 2, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical Products Administration (NMPA) to initiate a pivotal...
2026-09-02 17:00
2009
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent
Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026
SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical
2026-09-01 22:48
2705
REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch
Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora Canada stores. SEOUL, South Korea, Sept. 1, 2026 /PRNewswire/ -- REJURAN COSMETICS, the premium der...
2026-09-01 20:47
2332
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody targeting...
2026-09-01 20:28
3253
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
14322
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12990
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12140
